Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141

NCT04886531 is registered in ClinicalTrials.gov with Ruth O'Regan as lead sponsor.

NCT NCT04886531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04886531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141
Lead sponsor
Ruth O'Regan
Phase
Phase 2
Overall status
Recruiting
Start date
July 21, 2022
Completion date
December 21, 2027
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, er positive breast cancer, her2-positive breast cancer, pr-positive breast cancer